Drug intelligence / Profile preview

FMC3

Development stage: Preclinical
Lead developer: FimmCyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FMC3 is a preclinical-stage monoclonal antibody being developed by FimmCyte for the treatment of fibro-inflammatory diseases. It utilizes a non-hormonal approach designed to target fibrotic and fibro-inflammatory tissue directly. As of early 2024, the candidate is in the lead optimization stage, specifically within the discovery and in vivo testing phase. The specific molecular target of FMC3 has not been publicly disclosed by the company, but it is part of a platform focused on antibody-based therapies for conditions involving pathological fibrosis.

Beyond the preview

Go deeper on FMC3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FMC3.

Explore the full profile